News & Media

Admedus appoints new Chief Operating Officer

9, June, 2017

Posted In: Featured

Admedus Limited (Admedus) today announced the appointment of David St. Denis as the Company’s new Chief Operating Officer. He succeeds Julian Chick, who has recently resigned. St. Denis will take up the role in July after relocating to Minneapolis where he will be based. Read the full Company announcement here.

> Read more

Admedus HSV 2 Phase IIa Results – May 2017

8, May, 2017

Posted In: Videos, Uncategorized

> Watch the video

Admedus Investor Presentation – February 2017

28, February, 2017

Posted In: Videos, Uncategorized

> Read more

Admedus appoints new public relations consultancy

16, February, 2017

Posted In: In the media, Uncategorized

Admedus Limited (Admedus) today announced that Signal Leadership Communication Inc. (Signal) of Toronto has been appointed as its new public relations firm. Signal Principal Bob Pickard will personally serve as corporate communication counsel for Admedus. Read the full Company announcement here.

> Read more

CardioCel: 8 years on and still free from calcification

23, August, 2016

Posted In: Featured, Blog, Uncategorized

CardioCel® is proving to be one of the biggest game changers in the congenital heart defect repairs and reconstructions space, offering significant long-term benefits to patients. While other tissue patches can calcify up to 18 months post implantation in paediatric patients, the latest follow up data released by Admedus shows no evidence of calcification using […]

> Read more

Long-term CardioCel study shows no evidence of calcification after 8 years

22, August, 2016

Posted In: Uncategorized

Admedus Limited (ASX: AHZ) has today announced positive long-term data from its Phase II extension study for the repair of congenital heart defects in paediatrics using CardioCel. All patients continue to progress well, with no sign of calcification after 8 years or need for repeat procedures. Read the full Company announcement here.

> Read more

Long-term study indicates no calcification with CardioCel after eight years

22, August, 2016

Posted In: In the media, Uncategorized

Long-term data from a Phase II extension study for the repair of congenital heart defects in paediatrics using CardioCel shows that all patients continue to progress well, with no sign of calcification or need for repeat procedures.

> Read more

Admedus Investor Presentation – July 2016

26, July, 2016

Posted In: Videos, Uncategorized

> Watch the video

Using the ADAPT engineering process to create durable tissue scaffolds

8, July, 2016

Posted In: Featured, Blog, Uncategorized

Admedus is an Australian-based healthcare company leading the world in regenerative medicine and tissue engineering research. Using its proprietary ADAPT® tissue engineering technology, Admedus can transform xenograft (animal) tissue into durable bio-scaffolds that can be used for soft tissue repair within patients. The medical technology was first brought to Australia over 20 years ago by […]

> Read more

Admedus a major distributor of infusion solutions

10, June, 2016

Posted In: Blog, Uncategorized

Many people would have heard about the great work Admedus is doing in the field of tissue engineering and immunotherapies, but fewer people would know that Admedus is also a major distributor of infusion solutions (intravenous products and infusion pumps) to hospitals in Australia and New Zealand. The highly successful infusion portfolio has been part […]

> Read more